Coronavirus vaccine reaches phase-2 trials in China

Small bottles labeled with "Vaccine"stickers stand near a medical syringe in front of displayed "Coronavirus COVID-19"words in this illustration taken April 10, 2020. Reuters. Sketched by the Pan Pacific Agency.

BEIJING, Jun 21, 2020, China Daily. An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday (Jun 20), according to the China Daily.

The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.

So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.

Share it


Exclusive: Beyond the Covid-19 world's coverage